– PKU Phase 2 Data Panel Presentation –
– Poster Presentations on Phase 1 Homocystinuria (HCU) Data and Preclinical HCU Data –
CAMBRIDGE, Mass., March 7, 2023 (GLOBE NEWSWIRE) — Synlogic, Inc. SYBXthe leader in advancing synthetic biology-based therapeutics, today announced that it will present one panel presentation and two poster presentations at the Society for Inherited Metabolic Disorders (SIMD) 44th Annual meeting on March 19, 2023 in Salt Lake City, Utah.
- Panel presentation: Synpheny-1: A Phase 2 Efficacy and Safety Study of SYNB1618 and SYNB1934 in Patients With Phenylketonuria
- Presenting Author: dr Jerry Vockley, MD, PhD, Director, Center for Rare Disease Therapy, Principal, Medical Genetics at UPMC Children’s Hospital of Pittsburgh, Professor of Pediatrics and Human Genetics at the University of Pittsburgh, and Principal Investigator of PKU Phase 2 Synpheny-1 Study by Synlogic
- Date and Time: Sunday March 19, 2023 at 4:15 PM MT (6:15 PM ET)
- Poster Presentation #119: SYNB1353, a proposed therapy for homocystinuria, lowers plasma methionine and homocysteine in healthy volunteers exposed to methionine challenge
- Presenting Author: dr Neal Sondheimer, Medical Director, Synlogic
- Date and Time: Sunday March 19, 2023 at 8pm MT (10pm ET)
- Poster Presentation #95: Gastrointestinal Methionine Metabolism with Live Biotherapeutic SYNB1353 Leads to Improved Plasma Methionine and Homocysteine Levels in Mice and Non-Human Primates
- Presenting Author: dr Mylene Perreault, Vice President, Nonclinical Development and Biology, Synlogic
- Date and Time: Sunday March 19, 2023 at 8pm MT (10pm ET)
“We are excited to have the opportunity to present additional data for both the PKU and HCU programs at SIMD with the leading experts in inborn errors of metabolism,” said Dr. Dave Hava, Chief Scientific Officer and Head of Research and Development at Synlogic. “We recognize that PKU and HCU continue to place a tremendous burden on…
[ad_2]
Source story
